<DOC>
	<DOCNO>NCT00839683</DOCNO>
	<brief_summary>Phase A - To assess effect simvastatin pharmacokinetics ( PK ) dapagliflozin determine effect dapagliflozin PK simvastatin , simvastatin dapagliflozin coadministered healthy subject . Phase B - To assess effect valsartan PK dapagliflozin determine effect dapagliflozin PK valsartan , valsartan dapagliflozin coadministered healthy subject</brief_summary>
	<brief_title>Pharmacokinetic Drug Interaction Study Dapagliflozin Valsartan Simvastatin Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Healthy subject determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination Body Mass Index ( BMI ) 18 32 kg/m2 , inclusive . BMI = weight ( kg ) / [ height ( ) ] 2 Women childbearing potential unwilling unable use acceptable method avoid pregnancy entire study period 12 week last dose investigational product Abnormal urinalysis screening ( repeat urinalysis may allow positive hematuria woman ) Glucosuria screen Abnormal liver function test ( ALT , AST total bilirubin &gt; 10 % ULN ) Presence edema physical exam History diabetes mellitus History heart failure History renal insufficiency History chronic recurrent UTI ( define 3 occurrence per year ) UTI past 3 month History recurrent ( defined 3 occurences per year ) recent vulvovaginal mycotic infection Positive urine screen drug abuse either screen dose Positive blood screen hepatitis C antibody , hepatitis C antibody , hepatitis B surface antigen , HIV1 , 2 antibody History allergy SGLT2 inhibitor related compound History significant drug allergy ( anaphylaxis hepatotoxicity ) History allergy intolerance valsartan simvastatin ( related compound ) Prior exposure dapagliflozin , valsartan simvastatin within 3 month Day 1 Exposure investigational drug placebo within 4 week Day 1 Use prescription drug within 4 week overthecounter acid controller within 2 week prior study drug administration Use drug , include overthe counter medication within 1 week herbal preparation within 2 week prior admission study facility Use oral , injectable implantable hormonal contraceptive agent within 3 month Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>